CCL24 and neoplasm: The results indicated that CD31 was highly expressed in the control group, and tumor proliferation was significantly inhibited by the combination treatment of Ev‐siCCL24 and Bev (Figure 5F), indicating that the combination of CCL24 knockdown and anti‐angiogenic therapy may hinder the formation of tumor‐related neovasculature.